The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidée par micro-échographie, quel bénéfice ? Une analyse lésion par lésion.

Details

Serval ID
serval:BIB_CB1BFE80ABF7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidée par micro-échographie, quel bénéfice ? Une analyse lésion par lésion.
Journal
Progres en urologie
Author(s)
Martel P., Rakauskas A., Dagher J., La Rosa S., Meuwly J.Y., Roth B., Valerio M.
ISSN
1166-7087 (Print)
ISSN-L
1166-7087
Publication state
Published
Issued date
06/2022
Peer-reviewed
Oui
Volume
32
Number
6S1
Pages
6S26-6S32
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
- Microultrasound (MicroUS) is a novel imaging modality relying on a high-frequency transducer which confers a three-fold improvement in spatial resolution as compared with conventional transrectal ultrasound. We evaluated the diagnostic value of MRI-MicroUS fusion biopsy and determined the additional benefit of employing MicroUS.
- Retrospective analysis of consecutive treatment-naïve men undergoing MRI-MicroUS fusion biopsy between May 2018 and March 2019. Pre-biopsy MRI was systematically reviewed in a dedicated meeting where suspicious lesions PIRADS ≥ 3 were registered and uploaded in the ExactVu MicroUS device. MRI and MicroUS lesions were individually marked in a PIRADS v2 scheme. The biopsy protocol included MRI-MicroUS fusion and MicroUS targeted biopsies; systematic biopsies were performed at clinician's discretion. The diagnostic value was evaluated in terms of detection rate of clinically significant prostate cancer, defined as Gleason pattern ≥ 4 at histology.
- In all, 148 patients with a median age of 69 years (IQR 63-74) and median PSA density of 0.16 ng/ml/cc (0.10-0.23) were included. Clinically significant cancer was detected in 42.5% (63/148) patients. MRI detected 89 lesions in the peripheral zone; 73% (65/89) were visible on MicroUS. Clinically significant cancer was detected in 46.1% (30/65) MRI and MicroUS visible lesions, and in 4.2% (1/24) lesions only visible on mpMRI. MicroUS additionally identified 35 suspicious lesions non-visible on MRI of which clinically significant cancer was present in 25.7% (9/35).
- Adding MicroUS to the conventional pathway seems to increase the detection rate of clinically significant disease in unselected men undergoing biopsy. © 2022 Elsevier Masson SAS. All rights reserved.
Keywords
Male, Humans, Middle Aged, Aged, Retrospective Studies, Prostatic Neoplasms/diagnostic imaging, Prostatic Neoplasms/pathology, Image-Guided Biopsy/methods, Magnetic Resonance Imaging/methods, Ultrasonography, Biopsie de la prostate, Cancer de la prostate, Imagerie par résonance magnétique, Magnetic resonance imaging, Micro-échographie, Microultrasound, Prostate biopsy, Prostate cancer
Pubmed
Web of science
Create date
01/02/2023 17:47
Last modification date
30/03/2023 6:53
Usage data